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We read the recent Letter to the Editor by Dr Bridges 1 and thank him for his interest in our recent publications. 2, 3 In the course of his correspondence several incorrect statements were raised and, accordingly, we write to provide clarification.
The correspondent alludes to previous experimental studies (for example, those by Davidson et al. 4 ) demonstrating gene transfer using open-chest cardiopulmonary bypass. Although demonstrating gene transfer to the large animal heart, the implications of these studies are very limited clinically, given that the majority of patients with advanced heart failure who may potentially benefit from gene delivery do not require cardiac surgery for other reasons such as coronary artery bypass grafting. Clearly, for patients with advanced heart failure, the risk of cardiopulmonary bypass and the attendant requirement for cardiac arrest and cardioplegic perfusion would be substantial, particularly as the potential benefit of gene delivery would not be realized immediately. Accordingly, following early pilot studies performed nearly a decade ago, we came to the conclusion that a cardiac surgical approach for recirculating gene delivery would have very little to offer in the routine care of patients with advanced heart failure. With this in mind, we developed a platform technology that could allow for the optimal delivery of gene therapy to the failing human heart using a nonsurgical physiological perfusion-based approach. As such, in our previous and more recent publication, we described the application of a novel percutaneous gene transfer system for the delivery of viral vectors encoding genes for well-validated targets in the failing heart. The technique described uses a recirculating principle based on the intracoronary delivery of a relevant agent with recollection from the coronary sinus, with subsequent oxygenation and reinfusion of the captured blood into the coronary artery.
The original description of our recirculating gene delivery system provides a comprehensive description of the components and function of the system. 2 As previously described, a purpose-designed balloon occlusion catheter, together with a separate structural support element, was placed within the coronary sinus to facilitate capture of the coronary venous effluent. The hemiazygous vein was occluded by appropriate positioning of the occlusive balloon or, in cases in which this was not possible, with a second smaller balloon catheter. Pump flow rates were typically 100-120 ml min
À1
, and were achieved at a pump head pressure of À80 to À100 mm Hg. These data are entirely consistent with previous reports of coronary sinus blood flow rates in our previous studies (unpublished data) and in those of others. 5 In his letter, the correspondent describes 'normal coronary flows of 300 mls/min', although presumably this is in the setting of cardioplegia and in the presence of a supra-physiological perfusion pressure.
With regard to the efficiency of the recirculation system, it is stated that our recirculation system results in the loss of more than '99% of the vector'. As originally described, 2 our approach at the conclusion of the 10-min gene delivery cycle is to discard the remaining material from the circuit by draining the system for a period of 2 min. The total volume of the perfusion circuit used in our studies is 120 ml, thereby resulting in approximately 10 cycles of recirculation, in contrast to that proposed by Bridges. In his commentary, Bridges also highlights the presence of a vector in the liver in our study. We acknowledge that leakage from our system likely accounts for this observation, as is typically seen with all other forms of regional delivery. Future developments in viral particle tropism may reduce systemic appearance by enhancing uptake into the myocardium.
In his commentary, Bridges also states that our study did not provide evidence of functional improvement in cardiac performance. We appreciate that there was some baseline variability in contractile function between the treatment groups, in part because of the small sample size of our study and possibly also because of the inherent limitations of the reproducibility of echocardiographic measurement of ejection fraction. To present further confirmation of our conclusions, we conducted a further analysis of our data by combining the data obtained from the cohorts receiving medium-and high-dose AAV2/1-SERCA (1 Â 10 12 and 1 Â 10
13
, respectively). In control HF animals, left-ventricular ejection fraction (LVEF) and dP/dt were 37 ± 3% and 768 ± 51 mm Hg s
À1
, respectively, at day 34 and 32±2% and 776 ± 56 mm Hg s
, respectively, at follow-up. In AAV2/ 1-SERCA-treated animals, the LVEF and dP/dt were 34 ± 2% and 769 ± 35 mm Hg s
, respectively, at day 34 and 38±2% and 958±46 mm Hg s
, respectively, at follow-up. For both LVEF and +dP/dt, the betweengroup response differed significantly (Po0.05).
We look forward to ongoing developments in the complementary fields of vector biology for gene transfer and in approaches to gene delivery, with the ultimate intent of providing new clinically applicable approaches to the management of patients with advanced heart failure.
